EcoDrugPlus

Neuropeptide Y Receptor Type 2-Like

Ensembl ID : ENSHBUG00000000481
Gene Symbol: LOC102310244
3 Cross references
176 Possible Orthologues:

Neuropeptide Y Receptor Type 4-Like

Ensembl ID : ENSHBUG00000022980
Gene Symbol: LOC102307312
3 Cross references
135 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSHBUG00000008346
Gene Symbol: NTSR1
1 Cross references
203 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 1

Ensembl ID : ENSHBUG00000008795
Gene Symbol: NTRK1
3 Cross references
199 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSHBUG00000010215
Gene Symbol: NTRK2
3 Cross references
206 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSHBUG00000004723
Gene Symbol: NTRK3
3 Cross references
202 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSHBUG00000019944
Gene Symbol: NTRK3
3 Cross references
192 Possible Orthologues:

Nicastrin

Ensembl ID : ENSHBUG00000007596
Gene Symbol: NCSTN
4 Cross references
203 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSHBUG00000021131
Gene Symbol: NAMPT
3 Cross references
225 Possible Orthologues:

Notch Receptor 1

Ensembl ID : ENSHBUG00000012147
Gene Symbol: NOTCH1
3 Cross references
201 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSHBUG00000004157
Gene Symbol: NFKB1
3 Cross references
200 Possible Orthologues:

Nuclear Factor, Erythroid 2 Like 2

Ensembl ID : ENSHBUG00000019783
Gene Symbol: NFE2L2
3 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).